Loading...

Idorsia Ltd

IDRSF•PNK
Healthcare
Biotechnology
$2.40
$0.15(6.67%)

Idorsia Ltd (IDRSF) Stock Overview

Explore Idorsia Ltd’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap505.8M
P/E Ratio-1.36
EPS (TTM)$-1.65
ROE0.24%
Fundamental Analysis

AI Price Forecasts

1 Week$2.28
1 Month$1.20
3 Months$1.17
1 Year Target$0.61

IDRSF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Idorsia Ltd (IDRSF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.61.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.36 and a market capitalization of 505.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
-26.17%
↓ 26.17%
Profit Growth
$-1.40
↑ 11.47%
EPS Growth
$-1.40
↑ 13.17%
Operating Margin
-317.82%
↑ 9.07%
ROE
24.44%
↑ 11.47%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0

Price Targets

Low$0.00
Average$0.00
High$0.00

Company Profile

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

CEO

Andre C. Muller

Employees

1,100

Headquarters

Hegenheimermattweg 91, Allschwil

Founded

2017

Frequently Asked Questions

;